title: News on HIV-HCV Coinfection: Update From the 2015 GEHEP Conference.
abstract: New therapeutic options for the treatment of HCV infection are highly effective, possess minimal side effects, and allow for a shortened course of therapy, presenting a favorable scenario to treat and cure all patients chronically infected with HCV. However, there are still many challenges to advancement towards HCV eradication, not only related to the cost and the availability of the drugs, but also pertaining to epidemiologic, diagnostic, and treatment issues that remain to be resolved. Advances in the knowledge of all these topics are essential for the optimization of diagnostic and treatment strategies to fight again HCV infection. The latest data presented at the I Conference of the Group for the Study of Viral Hepatitis (GEHEP) (23-26 September, Spain) highlights relevant progress on many of these fronts for an overview of HCV infection at present. This review summarizes some of the major findings presented and discussed during the conference.
authors.affiliation: Division of Clinical Virology, Instituto de Investigación Biomédica de A Coruña (INIBIC)-Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas, Universidade da Coruña (UDC), A Coruña, Spain.
authors.forename: Eva
authors.initials: E
authors.lastname: Poveda
authors.affiliation: Infectious Disease Division, University of California, San Diego, USA.
authors.forename: David
authors.initials: D
authors.lastname: Wyles
authors.affiliation: Unit of Infectious Diseases, University Hospital Álvaro Cunqueiro, Vigo, Spain.
authors.forename: Luis
authors.initials: L
authors.lastname: Morano
authors.affiliation: Unit of Infectious Diseases and Microbiology, Hospital Universitario de Valme, Seville, Spain.
authors.forename: Juan Antonio
authors.initials: JA
authors.lastname: Pineda
authors.affiliation: Department of Microbiology, Instituto de Investigación Biosanitaria (IBIS)-Complejo Hospitalario Universitario de Granada, Granada, Spain.
authors.forename: Federico
authors.initials: F
authors.lastname: García
mesh_terms: D017088:AIDS-Related Opportunistic Infections / Q000188:drug therapy* / Q000517:prevention & control; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D023241:Antiretroviral Therapy, Highly Active; D000998:Antiviral Agents / Q000627:therapeutic use*; D060085:Coinfection; D003226:Congresses as Topic; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy* / Q000276:immunology; D019698:Hepatitis C, Chronic / Q000188:drug therapy* / Q000209:etiology / Q000276:immunology; D006801:Humans; D011379:Prognosis; D016896:Treatment Outcome
chemical_list: D019380:Anti-HIV Agents; D000998:Antiviral Agents